Genomic technology has rapidly created a multi-billion dollar growth industry. With life sciences companies scrambling in US and European courts for a share of the lucrative market, in-house IP counsel should start preparing for the next wave of IP litigation, explain Dominic Adair and Annsley Merelle Ward
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
VLSI case halted in Delaware; Netflix sues Bridgerton rip-off; Ex-GSK scientist escapes damages; US Copyright Office debuts new software; Abbvie scores Humira patent thicket win; Russia tables bill on illegal blocking of copyrighted content